Alphyn is developing breakthrough therapies for the most challenging, severe, and common skin diseases using its proprietary Zabalafin (AB-101) Platform for Multi-Target Therapeutics™. The Company’s lead product candidate, Zabalafin Hydrogel, is being developed as the first therapeutic for atopic dermatitis (AD) to directly treat AD’s itch and directly treat bacteria that are increasingly thought to cause AD’s inflammation and flares. It also directly treats infected AD skin and directly treats inflammation. Zabalafin Hydrogel’s Phase 2a clinical trial results were better than competitive drugs, pointing to it becoming the “drug of choice” to treat AD, reportedly the largest dermatology problem worldwide, with a projected $118 Billion global market. Alphyn anticipates initiating a larger Phase 2b clinical trial program for AD in January 2025, and clinical trials for its second candidate for epidermolysis bullosa, a collection of rare skin diseases, later in the year.